Studies On The Pharmacokinetics And Bioavailability Of Yjs Capsules In Dogs

20(S)-proto-panaxdiol had strong anti-cancer activities. It affected many links of cancer. And it is low-poisonous and safe, so it has broad prospects of developing and applying. In this study, the pharmacokinetics and bioavailability of 20(S)-proto-panaxdiol was investigated by means of LC/MS/MS. The study should be helpful for acquiring deep understanding of metabolism of 20(S)-proto-panaxdiol in vivo. 1,Determination of 20(S)-proto-panaxdiol in dogs plasma using a LC/MS/MS method. A specific and sensitive method for the Simultaneous determination of 20(S)-proto-panaxdiol in dog plasma using LC/MS/MS was developed. The samples were co-extracted with gensenoside Rh2, the internal standard, and analyzed Zorbax Extend C18 column at 40℃by pumping methanol-acetonitrile-10mmol.L-1ammonium acetate (45:45:10, v/v/v). Flow rate is 0.4ml.min-1.yjs capsules and internal standard gensenoside-Rh2 were extracted from plasma with liquid-liquid extraction, then Separated on a Zorbax Extend C18 column. The mobile phase consisted of methanol-acetonitrile-10mmol.L-1 ammonium acetate (45:45:10, v/v/v).Ion spray ionization (ISI) Source was applied and operated in positive ion mode. Selected MRM mode with the transitions of m/z 461.6 →m/z 425.5,m/z 623.50→m/z 605.5 was used to quantify 20(S)-proto-panaxdiol and internal standard(gensenoside Rh2). The method has been validated by international standard. 2,Studies on the pharmacokinetics and bioavailability of 20(S)-proto-panaxdiol in dogs. According to the method, the plasma samples which were collected from 6 healthy dogs after IV and oral administrations of yjs-capsules (50 mg) were determined and the plasma concentration-time profiles were obtained. According to the profiles, the main pharmacokinetic...